Afya-Yduqs Merger Creates R$9.4bn Brazilian Education Group

Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review by Brazil’s Cade (Conselho Administrativo de Defesa Econômica).

A crane lowers a smaller mortarboard-shaped block into a matching gap in a larger mortarboard structure, with tiny silhouettes standing nearby.

MERGERS & ACQUISITIONS · MEDICAL EDUCATION · SEPTEMBER 29, 2026 · BRAZIL

Two of Brazil’s largest private education groups formalized a merger on September 23, 2026, creating a combined entity with R$9.4 billion in net revenue over the 12 months to June 2026 — and concentrating roughly 5,900 annual medical-school seats authorized by the Ministério da Educação (Ministry of Education) under a single ownership structure, according to the companies’ announcement.

The deal pairs Afya, a medical-education group controlled by the German media and education conglomerate Bertelsmann, with Yduqs, the Rio de Janeiro-based group that owns Estácio, Ibmec, and Wyden. Formally, Yduqs incorporates Afya, which will delist from the Nasdaq. In practice, Afya’s shareholders take 69% of the combined entity and Yduqs shareholders 31%, per the exchange ratio of about 6.4 new Yduqs shares for each Afya share. Bertelsmann, Afya’s controlling shareholder, will hold approximately 47% of the combined company and the right to appoint a majority of the board, according to the companies. Kay Krafft, chief executive of Bertelsmann Education, will chair the board; Virgilio Gibbon, current chief executive of Afya, will serve as chief executive of the merged group, and Rossano Marques, Yduqs’s chief executive, will become president of higher education excluding medicine.

R$9.4bn

The combined group recorded R$9.4 billion in net revenue over the 12 months to June 2026, with medicine accounting for approximately 45% of the total, per the companies.

The premium-segment logic

Medicine accounts for approximately 45% of the combined R$9.4 billion in net revenue, according to the companies. The combined group will hold 55% of its net revenue and about two-thirds of its earnings before interest, taxes, depreciation, and amortization (EBITDA) in premium segments — medical education and Ibmec — according to the companies. Afya operates 32 medical schools and Yduqs 19 through its Idomed unit, according to InvestNews; across all segments, the combined group will have 176 campuses in 26 states, per Yduqs.

The financial architecture reflects that premium concentration. The combined group has guided synergies of R$2 billion to R$2.2 billion — including the elimination of duplicated technology and student-service structures and the integration of shared service centers, according to Sem Pauta’s account of comments by Alexandre Aquino, Yduqs’s chief financial officer. The companies project 80% of those synergies to be captured within three years. The combined company intends a 50% dividend payout on net income after closing and will start with leverage of approximately 1.2 times net debt to adjusted EBITDA, per Yduqs; Marques described the group’s view of acquisitions as opportunistic.

Yduqs shareholders receive a minimum R$750 million in dividends between signing and closing, and a 45% premium over Yduqs’s 30-day volume-weighted average price, according to Money Times. The four reference shareholders — Bertelsmann, the Esteves family with 7.6%, Advent with 5.3%, and the Zaher family with 4.8% — will sign a new shareholders’ agreement with a 180-day lock-up on all or part of their shares. The free float is expected to settle at approximately 35%, according to Exame.

The Cade variable

The transaction is subject to approval by Cade (Conselho Administrativo de Defesa Econômica, Brazil’s antitrust authority) and by the shareholders of both companies. The Cade filing is expected in about 15 days, according to Sem Pauta. Yduqs’s shareholder meeting is expected to be called in October and held in November, according to Sem Pauta. The companies expect the transaction to close within 12 months, with a contractual deadline of March 31, 2028.

The antitrust question is more granular than the national headline figure suggests. JP Morgan estimated the combined group would hold 17% of private medical-school seats in Brazil (Afya about 11%, Yduqs 6%), according to Money Times. Exame reported, citing XP and BTG calculations, that when the analysis is conducted city by city rather than nationally, the combined seat share could be materially higher in specific markets.

BTG Pactual analysts Samuel Alves and Maria Resende, writing in a note cited by Exame, argued that the deal is primarily protective for Yduqs shareholders: ‘We believe the alternative scenario would have been considerably less attractive, as Yduqs shares would likely have faced significant pressure had the transaction not advanced.’ Yduqs’s digital (distance-learning) revenue fell 15.2% in the second quarter of 2026, while hybrid-format revenue rose 38.2%, according to BPMoney, which attributed the shift to new distance-education rules. Afya’s undergraduate segment, by contrast, grew revenue 7.4% in the first half of 2026 to R$1.76 billion, with the medical student base expanding 2.7% to 26,421 students, per Afya’s first-half results. The merger gives Yduqs access to that growth engine; whether the synergy projections survive the operational complexity of integrating the two groups’ medical schools is a separate question.

What to Watch

  1. Cade’s geographic concentration analysis, particularly in cities where Afya and Idomed both hold authorized seats — any remedies imposed at that level would directly affect the combined group’s premium revenue base
  2. Shareholder approvals at both companies, with Yduqs’s meeting expected in November 2026
  3. The pace of synergy capture against the target of 80% within three years, including the removal of duplicated technology and student-service structures cited by management
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper structural signal is that Bertelsmann, through this transaction, converts a Nasdaq-listed Brazilian medical-education bet into a controlling stake in a diversified higher-education platform listed solely on the B3 (Brasil, Bolsa, Balcão), São Paulo’s stock exchange, concentrating both the upside and the regulatory exposure of Brazilian medical-seat policy in a single vehicle.

Afya-Yduqs Combined Entity · Key Metrics

Metric Value
Combined net revenue (12 months to June 2026) R$9.4 billion
Annual medical-school seats authorized ~5,900
Medicine share of combined net revenue ~45%
Premium segments (medicine and Ibmec) share of combined EBITDA About two-thirds
Projected synergies (present value, company guidance) R$2 billion to R$2.2 billion
Share of Brazil’s private medical-school seats (JP Morgan estimate) 17%
Bertelsmann stake in combined company ~47%

Sources: Afya and Yduqs merger announcements; Money Times (JP Morgan estimate)

Why this is relevant

Patients

The combined group will hold approximately 5,900 annual authorized medical-school seats, a scale that may be associated with broader geographic distribution of physician training over time, though the pace depends on Cade approval conditions and operational integration.

Industry

The merger creates a larger private medical-education platform with R$9.4 billion in combined net revenue and guided synergies of R$2 billion to R$2.2 billion, 80% targeted within three years; competitors in premium medical education face a structurally larger and better-capitalized rival.

Payers

Concentration of medical-seat supply under a single group holding a JP Morgan-estimated 17% of private medical-school seats could, over time, influence the geographic and specialty distribution of graduating physicians available to public and private health networks, though this remains a long-horizon effect.

Regulators

The Cade filing was expected in about 15 days, according to Sem Pauta; analysts at JP Morgan, XP and BTG flagged high city-level seat overlap in Ji-Paraná, Teresina and Rio de Janeiro, with Yduqs’s shareholder meeting expected in November 2026.

Sources: Afya: merger announcement (US Securities and Exchange Commission filing) · Yduqs: announcement of the combination with Afya · Afya: first-half 2026 results (SEC filing) · Exame: Onde a fusão entre Yduqs e Afya acerta — e onde pode tropeçar · Sem Pauta: Fusão entre Yduqs e Afya cria gigante da educação com 5,9 mil vagas de medicina · Money Times: JP Morgan on the Afya-Yduqs merger · Money Times: Yduqs-Afya merger and dividends · InfoMoney: market reaction to the Yduqs-Afya combination · InvestNews: Afya and Yduqs in medical-school seats · BPMoney: Yduqs second-quarter 2026 results

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related